Efficacy Study of Phytotherapy "Raylis" In Congestive Processes Of The Pelvic Organs (Prostatostasis)
Phase 3 Study of Phytotherapy "Raylis" In Congestive Processes Of The Pelvic Organs (Prostatostasis)Caused By Decrease Of Sexual Activity In Men.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Yuliya Tishova, MD PhD
- Phone Number: +79032213276
- Email: yulya_tishova@mail.ru
Study Locations
-
-
-
Moscow, Russian Federation, 123242
- Recruiting
- Clinic Of Men's Health and Couple Longevity
-
Contact:
- Yuliya Tishova, MD PhD
- Phone Number: +79032213276
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 20-60 years
- Symptoms of prostatostasis lasting for at least 3 months during the past 6 months:
- Pathological changes on uroflowmetry (maximum flow rate of less than 15 ml / s, average urinary flow rate of less than 12 ml / sec)
- TRUS Prostate volume more than 22 ml at TRUS
- TRUS picture of Prostatostasis
- I-PSS 7-20
- IIEF-5) - 12-21
Exclusion Criteria:
- Contraindications and limitations to use of the drug Raylis listed in the instructions for medical use *
- Diabetes mellitus (type 1 and type 2, decompensation)
- Neurogenic disorders (acute cerebral circulatory disorders, Alzheimer's disease, spinal cord injury)
- A history of pelvic trauma
- Patients who had undergone radical prostatectomy and other surgical interventions on the pelvic organs
- Concomitant use of supplements to improve the erectile function, use of the anti-androgens, anti-depressants, finasteride.
- Diagnosed BPH
- Current participation in a clinical trial and / or study medication for 30 days prior to inclusion
- Any form of substance abuse, mental disorder or condition which, in the opinion of the investigator, may complicate communication with the researcher.
- The inability or unwillingness to comply with the scheme of visits according to protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Raylis
This arm (10 men with symptoms of prostatostasis) will get "Raylis" (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months
|
"Raylis" (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)
|
|
Active Comparator: standard prostatostasis therapy
This arm (20 men with symptoms of prostatostasis) will get the standard (pathogenetic) therapy of prostatostasis
|
|
|
Experimental: Raylis plus standard prostatostasis therapy
This arm (20 men with symptoms of prostatostasis) will get "Raylis" (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months together with standard prostatostasis therapy
|
"Raylis" (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
TRUS prostate
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Uroflowmetry
Time Frame: 3 months
|
3 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
IPSS
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Svetlana Kalinchenko, MD PhD, Clinic of Men's Health and Couple Longevity, str Zoologicheskaya, 2-7 Moscow Russia
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MHCL-01-15052013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.